Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis
Authors:
Open Access
- 8 November 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (11) , e0166230
Abstract
Recently, numerous studies have reported that hexokinase-2 (HK2) is aberrantly expressed in cancer, indicating that HK2 plays a pivotal role in the development and progression of cancer. However, its prognostic significance in solid tumor remains unclear. Accordingly, we performed a meta-analysis to assess the prognostic value of HK2 in solid tumor. Eligible studies were identified using PubMed, Embase, and Web of Science databases. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) or progression-free survival (PFS)/disease-free survival (DFS)/relapse-free survival (RFS) were estimated with random effects or fixed effects models, respectively. Subgroup analysis was also performed according to patients’ ethnicities, tumor types, detection methods, and analysis types. Data from 21 included studies with 2532 patients were summarized. HK2 overexpression was significantly associated with worse OS (pooled HR = 1.90, 95% CI = 1.51–2.38, p < 0.001) and PFS (pooled HR = 2.91, 95% CI = 2.02–4.22, p < 0.001) in solid tumor. As to a specific form of cancer, the negative effect of HK2 on OS was observed in hepatocellular carcinoma (pooled HR = 2.06, 95% CI = 1.67–2.54, p < 0.001), gastric cancer (pooled HR = 1.72, 95% CI = 1.09–2.71, p = 0.020), colorectal cancer (pooled HR = 2.89, 95% CI = 1.62–5.16, p < 0.001), but not in pancreatic cancer (pooled HR = 1.13, 95% CI = 0.28–4.66, p = 0.864). No publication bias was found in the included studies for OS (Begg’s test, p = 0.325; Egger’s test, p = 0.441). In this meta-analysis, we identified that elevated HK2 expression was significantly associated with shorter OS and PFS in patients with solid tumor, but the association varies according to cancer type.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2015CB5540007)
- National Natural Science Foundation of China (81472740)
- National Natural Science Foundation of China (81101825)
- Health and Family Plan Committee of China (201402015)
This publication has 44 references indexed in Scilit:
- Choline Kinase Alpha and Hexokinase-2 Protein Expression in Hepatocellular Carcinoma: Association with SurvivalPLOS ONE, 2012
- The Pancreas Cancer MicroenvironmentClinical Cancer Research, 2012
- Long Term Prognostic Implications of Expression of Glucose Transporter-1 and Hexokinase II in Patients with Stage I Uterine LeiomyosarcomaACTA HISTOCHEMICA ET CYTOCHEMICA, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiformeJournal of Experimental Medicine, 2011
- Analyses of Resected Human Brain Metastases of Breast Cancer Reveal the Association between Up-Regulation of Hexokinase 2 and Poor PrognosisMolecular Cancer Research, 2009
- Hexokinase-2 bound to mitochondria: Cancer's stygian link to the “Warburg effect” and a pivotal target for effective therapySeminars in Cancer Biology, 2009
- Glucose Phosphorylation and Mitochondrial Binding Are Required for the Protective Effects of Hexokinases I and IIMolecular and Cellular Biology, 2008
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002